Related Experiment Video
Updated: Mar 3, 2026
09:28
One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
Published on: June 25, 2010
13.6K
Neonatal Screening: Cost-utility Analysis for Galactosemia
Nahid Hatam1, Mehrdad Askarian2, Samad Shirvani3
1Dept. of Health Services Management, School of Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Iranian Journal of Public Health
|April 29, 2017
Summary
Neonatal screening for galactosemia is cost-effective, improving infant health and saving healthcare resources. This program offers significant financial benefits and enhances quality of life.
Area of Science:
- Medical Economics
- Public Health
- Neonatal Care
Background:
- Galactosemia is a serious congenital metabolic disorder affecting newborns.
- Early screening is crucial for preventing severe health complications.
- Economic analysis is vital for optimizing healthcare resource allocation.
Purpose of the Study:
- To evaluate the cost-utility of a neonatal screening program for galactosemia.
- To analyze the economic impact of screening in Fars province, Iran.
Main Methods:
- Cross-sectional study utilizing a decision tree model from a societal perspective.
- Involved 81,837 infants screened in 2010.
- Quality of life assessed using time trade-off; cost-effectiveness determined by Incremental Cost-effectiveness Ratio.
Main Results:
- Screening costs were significantly lower than costs without screening (43,519,911 vs. 130,011,168 Iranian Rails).
- An annual saving of 201,443,240.99 Iranian Rails ($19,641.00) per patient was observed.
- Screening demonstrated a positive economic impact.
Conclusions:
- The neonatal screening program for galactosemia improves quality of life and generates healthcare savings.
- Results support the implementation of screening policies to enhance public health outcomes.
- Screening is a valuable investment for the healthcare system.
